Abbott
ABT
Market cap $233B

132.02 USD

-1.58

1.18%

At close Jul 11, 4:00 PM EDT

After hours

132.05

+0.03

0.02%

1 day

-1.18%

5 days

-1.85%

1 month

-2.41%

3 months

4.05%

6 months

16.64%

Year to date

16.38%

1 year

26.72%

5 years

41.82%

10 years

165.53%

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Medical Devices

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

129% more first-time investments, than exits

New positions opened: 268 | Existing positions closed: 117

58% more funds holding in top 10

Funds holding in top 10: 72 [Q4 2024] → 114 (+42) [Q1 2025]

17% more call options, than puts

Call options by funds: $1.38B | Put options by funds: $1.18B

15% more capital invested

Capital invested by funds: $155B [Q4 2024] → $178B (+$23.4B) [Q1 2025]

3% more funds holding

Funds holding: 3,014 [Q4 2024] → 3,102 (+88) [Q1 2025]

0.06% more ownership

Funds ownership: 77.55% [Q4 2024] → 77.61% (+0.06%) [Q1 2025]

15% less repeat investments, than reductions

Existing positions increased: 1,120 | Existing positions reduced: 1,318

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$127

4%

downside

Avg. target

$144

9%

upside

High target

$159

20%

upside

9 analyst ratings

7 positive

78%

2 neutral

22%

0 negative

0%

Evercore ISI Group Vijay Kumar	10%upside $145	Outperform Maintained	8 Jul 2025
Raymond James Jayson Bedford	8%upside $142	Outperform Maintained	17 Apr 2025
Piper Sandler Adam Maeder	10%upside $145	Overweight Reiterated	17 Apr 2025
RBC Capital Shagun Singh	10%upside $145	Outperform Maintained	17 Apr 2025
Wells Fargo Lawrence Biegelsen	11%upside $147	Overweight Maintained	17 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 26 articles about ABT published over the past 30 days

Zacks Investment Research

Abbott (ABT) Suffers a Larger Drop Than the General Market: Key Insights

Abbott (ABT) reached $132.02 at the closing of the latest trading day, reflecting a -1.18% change compared to its last close.

Abbott (ABT) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research

Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.

ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

Should You Buy Abbott Stock At $135?

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the company's solid quarterly results and positive future forecasts.

Should You Buy Abbott Stock At $135?

The Motley Fool

2 Dividend Stocks to Buy for Decades of Passive Income

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.

2 Dividend Stocks to Buy for Decades of Passive Income

Zacks Investment Research

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

Zacks Investment Research

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

Zacks Investment Research

Abbott (ABT) Upgraded to Buy: Here's What You Should Know

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Abbott (ABT) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion

ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.

Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion

Zacks Investment Research

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

See News Rankings

Charts implemented using Lightweight Charts™